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Evidence for a positive association between blood pressure and sodium excretion has been found in several large observational studies (1) (2) (3) , both between and within populations. Clinical trials of sodium reduction and blood pressure have generally supported this relation (4, 5) , but the size of the effect remains controversial, especially in normotensive populations (6, 7) . A recent meta-analysis of randomized trial data (8) estimated an average reduction in systolic/diastolic blood pressure of 4.8/2.5 mmHg with dietary sodium reduction intervention among hypertensive subjects, and of 1.9/1.1 mmHg among normotensive subjects.
The effects on blood pressure in any trial depend on the extent of the sodium reduction achieved. However, estimates of dose-response are problematic due to the high degree of within-person variability in measures of both sodium excretion and blood pressure (9, 10) . Investigators in the Intersalt Study used statistical adjustment to correct for the within-person variability in cross-sectional data within and between populations (11, 12) . However, the appropriateness of these corrections has been questioned, particularly due to the cross-sectional nature of the data, and a lack of correction for within-person covariability between blood pressure and sodium excretion (13, 14) .
We address this issue using longitudinal data from the sodium reduction component of Phase I of the Trials of Hypertension Prevention (TOHP I) carried out in 1987-1990 (15) . This trial, conducted among participants with diastolic blood pressure in the high normal range (80-89 mmHg), was designed to test the impact of seven nonpharmacologic interventions, including both life-style and dietary supplement interventions, on blood pressure over either a 6-month or 18-month period (16) . The analyses reported here ad-432 Cook et al. just for within-person variability in estimating the relation of change in blood pressure with change in sodium excretion. Thus, we estimate the longitudinal effects of sodium reduction on changes in blood pressure, which are subject to less confounding than crosssectional estimates. We include corrections for both within-person (week-to-week) variability and covariability of sodium excretion and blood pressure.
MATERIALS AND METHODS
In TOHP I, repeat measures of both blood pressure and urinary excretion variables were taken over a series of screening visits at baseline and at regular follow-up intervals. Variability of sodium and potassium excretion and the sodium-potassium ratio (Na/K), along with their covariability with other measures, were estimated both for persons randomized to the sodium intervention or its control and for the entire screened population.
TOHP I screening population
A total of 16,821 individuals was screened at 10 clinical centers for eligibility for Phase I of TOHP. Screening took place over a series of three approximately weekly visits (SV1-SV3) in which eligibility criteria were evaluated. Eligible participants were aged 30-54 years, with no evidence of cardiovascular disease, no contraindications to any of the TOHP I interventions, and no evidence of inability to comply with the TOHP I interventions. Detailed eligibility criteria have been published elsewhere (17) .
Blood pressure screening was a part of the three baseline visits. Three measurements of blood pressure were taken at each visit by carefully trained and certified staff using the Hawksley random-zero sphygmomanometer (Hawksley and Sons, Ltd., West Sussex, England) after the participant was sitting at rest for at least 5 minutes. The final blood pressure eligibility criterion for TOHP I was a mean diastolic blood pressure, averaged over all three screening visits (SV1-SV3), in the range 80-89 mmHg. To accomplish this, ranges for eligibility based on diastolic blood pressure were established for the initial screening visits based on a predictive value rule (18) . These ranges were 75-97 mmHg at SV1 and 77-94 mmHg averaged over SV1 and SV2 (see figure 1) .
As shown in figure 1 , a urine specimen covering a recent 24-hour period was collected at SV3 and at a status review visit (SRV), at which final eligibility was established and treatment allocation was determined. Height and weight were measured at SV1. A second weight measure taken at SV3 was used as the baseline measure in the trial.
Of the 16,821 study candidates screened at SV1, 7,362 (44 percent) were eligible and returned for SV2, and 4,560 (27 percent) remained eligible and returned for SV3 (19) . A total of 2,182 participants were ultimately randomized into one of the interventions of Phase I. The most limiting eligibility criterion was blood pressure, with approximately 58 percent of screened participants found to be outside of the range at one of the visits. Another 15 percent were initially eligible but did not return for all screening visits (18) . Approximately 15 percent of screening candidates were ineligible for reasons other than blood pressure or willingness to participate, leaving 14,360 screened participants who fulfilled eligibility criteria except for blood pressure or willingness.
Sodium intervention data
A total of 327 men and women were randomized into the active sodium reduction intervention and 417 into its usual care comparison group in six clinical centers. The objective of the sodium intervention was to reduce urinary sodium excretion to an average of 80 mmol/24 hours in the active group (15) . Follow-up measures of sodium excretion were collected at 6, 12, and 18 months of follow-up, with one 24-hour urine collection at each of these times. Weight was also measured once at each follow-up.
The primary outcome of the trial was change in diastolic blood pressure at the end of follow-up at 18 months, with change in systolic blood pressure as a secondary outcome. Follow-up blood pressure measurements were taken at 6, 12, and 18 months, with measurements taken and averaged over a series of three clinic visits at 12 and 18 months, and at a single visit at 6 months. Three blood pressure measurements were taken at each visit.
Statistical methods
The distribution of measures of sodium, potassium, and the sodium-potassium ratio (Na/K ratio) were skewed, with a long tail at the higher values. The square root transform tended to normalize the data, and did so more effectively than a log transform. The square root transform (indicated by VNa) also normalized the distribution of change over time, stabilized the variances, and increased the observed correlations over time. Selected results are also presented for data in the original scale.
Estimates of between-and within-person variance were obtained from the total screened population, and, for the subset that was randomized to the sodium intervention or its control, from blood pressure data obtained at both the baseline and 18-month follow-up visits. For the total screened population, those who did not meet the blood pressure eligibility requirements or who were unwilling to participate in the trial were allowed to contribute to the estimation of variance components. Data on 14,360 participants who fulfilled all other eligibility criteria were included in this analysis. Multivariate models based on such data can appropriately estimate the overall variance structure using maximum likelihood methods (20, 21) . Data missing due to blood pressure ineligibility were considered missing at random (MAR) (22) for purposes of variance estimation. That is, conditional on blood pressure values already observed in the study, including the out-of-range values, missingness at later visits was assumed to be unrelated to the unobserved levels at the later unattended visits. While the observed univariate variances of blood pressure would decrease over screening visits due to selection on blood pressure all of the data may be used to estimate the underlying variances and covariances without selection using multivariate methods which account for the correlation between visits. Variance estimates from the total screened group thus represent population estimates of these components.
Estimates of the between-and within-person variance and covariance components were obtained using a multivariate model including measures of both systolic and diastolic blood pressure (three visits each), and measures of sodium and potassium excretion (two visits each). The model was thus fit to a vector of 10 measures for each individual, allowing correlations between all measures and visits. A compound symmetry model, with equal variances and correlations across the screening visits, was assumed for the underlying population variance of each measure, and similar forms were fit to the covariances. The mean for each variable was adjusted for age (single years), sex, and race (black vs. other). Details of the model and the exact form of the variance structure are given in Appendix 1. Models were fit using program 5V of BMDP (23) .
Identical models were fit to the baseline screening data for the 744 participants randomized to the sodium intervention or control. Because of the highly selective screening rules for diastolic blood pressure at baseline, the variance components for these randomized individuals could be highly distorted. While these estimates are not generalizable to a wider population, they were used for error correction within the randomized groups. Variance components for blood pressure were estimated separately at 18 months of follow-up, and were used for correction. Because only one excretion was collected at 18 months, within-person variances of the excretion measures and covariances of these measures with blood pressure at 18 months were estimated from baseline values. Estimates from the total screened population rather than randomized estimates were used to reduce the influence of selection at baseline. While it is possible that the intervention may have altered these variance components by 18 months, it is likely that the intervention would affect betweenperson variances more than within-person variances.
Reliability, or the proportion of the total variance due to between-person variability, was estimated as
The reliability of measures taken at a single visit, as opposed to averaged across visits, is the same as the visit-to-visit correlation between measures. The within-person variance of the mean over visits is also a function of the number of visits. For change measures, the reliability is a function of the total variance of the change as well as the within-person variability of the change, usually a sum of within-person components for the measures at the two times. A covariance reliability (CR) was also calculated for combinations of two measures, defined as
Analogous to the reliability, this may be interpreted as the proportion of the covariance between variables that is due to between-person covariance. Unlike the reliability, however, the covariance reliability need not be strictly a proportion, since the between-and withinperson covariances may be of different signs. The covariance reliability for measures at a single visit is also equal to the ratio of the correlation of the measures at different visits to that at the same visit. The observed regressions of blood pressure on the excretion variables were obtained through leastsquares regression using PROC REG of SAS (24) . Change in blood pressure from baseline to 18 months was regressed on change in the excretion over the same period. For both measures, the mean of all values at either baseline (three visits for blood pressure, two visits for excretions) or 18 months (three visits for blood pressure, one visit for excretions) was used to compute the change. The square root transform was used for all excretion measures. Relations with blood pressure were similar in strength for excretions in the original and square-root scales. Other transformations, including the logarithmic, and the addition of polynomial terms, did not improve the fit. These regressions were adjusted for age, race, and sex. Regressions were run both with and without baseline blood pressure and excretion in the model. All regressions were done in the pooled sample of those in the active sodium intervention and in the sodium control group.
These observed regressions were corrected for within-person variability, using a multivariate error correction (25, 26) . All adjustments allowed for both the within-person variance of change in excretion and its within-person covariance with blood pressure. A multivariate correction was made for the withinperson variability of all variables in the model. The corrected coefficient vector /3 ad j takes the form
where X'X and X'Y represent the average uncorrected sum of squares and sum of crossproduct matrices for the predictor variables from the usual linear leastsquare regression, S uu is a matrix containing the within-person variances and covariances for the predictor variables, and S uw is a vector containing the within-person covariances with the outcome variable, change in blood pressure. The forms for these withinperson variances and covariances are given in Appendix 2. An expression for the variance of /3 adj is given in Appendix 3.
RESULTS

Descriptive data
Screening data were available for the 14,360 participants who fulfilled eligibility criteria other than for blood pressure and willingness. Average age in this population was 42 years, 57 percent were male, 83 percent were white, and 12 percent were black. The number of measures available at each screening visit, as well as means of the baseline variables, are given in table 1. The sequential blood pressure screening rules that were applied (figure 1) affected these distributions at later screening visits. Urine excretion data were available for 41 percent of participants seen at SV3.
Corresponding data for the 744 participants randomized into the sodium intervention or control group are also given in table 1. The average age in this randomized group was 43 years, 71 percent were male, 77 percent white, and 20 percent black. Because the target range for diastolic blood pressure was 80-89 mmHg averaged over all three screening visits (SV1-SV3), the means at each visit were higher than in the total screened population. Excretion data were available for 715 participants at either SV3 or SRV, or for 96 percent of those randomized. Mean excretion values were similar to those in the screened population at the later screening visits, except for sodium, which exhibited some extreme values in the screened population at SV3.
Estimates of variance components
Estimates of the variance components and reliabilities in the total population were first obtained from the population screened in TOHP I. The between-person and within-person variance components are given in table 2. The within-person variances for systolic and diastolic BP are for an average of three measurements taken at a single visit.
The correlation of mean blood pressures between visits, an estimate of the reliability of the mean of three blood pressures taken at one visit, was close to 0.7 for both systolic and diastolic blood pressure.
Correlations were lower for the excretion measures, at about 0.4 for all three measures. Reliabilities for the excretions are all based on the square root transform. Estimated reliabilities in the original scale were similar, but slightly lower in magnitude, at 0.34 for sodium, 0.39 for potassium, and 0.40 for the Na/K ratio. The estimated reliability for body mass index (BMI) was very high, at 0.98, although the within-person variability of BMI was non-zero, and was statistically significant (p < 0.05).
The between-and within-person covariance components are also given in table 2 for each combination of measures. These were all statistically significant {p < Q.Q5) except for the within-person covariances of VNa and blood pressure. In likelihood ratio tests of the covariance parameters, the within-person covariances of VNa with both systolic and diastolic blood pressure were not significant (p > 0.05), particularly that with diastolic blood pressure. Because both of these within-person covariances were non-zero, however, and in the expected direction, they were used in the correction. The between-person covariance of VK and systolic blood pressure also was not statistically significant in these data.
The correlations in table 2 are those for measures taken either at the same visit or at different visits spaced approximately one week apart. The difference in these two correlations reflects the degree of withinperson covariability. For blood pressure, the correlation of systolic and diastolic blood pressure at the same visit was 0.67, while that for different visits was 0.53. The correlations between the excretions and blood pressure at a single visit were generally low, while that between VNa and VK at the same visit (and same urine collection) reached 0.47, with a correlation of 0.14 for different visits.
Corresponding variance components based on only the sample of participants randomized to the active sodium intervention or its control are given in table 3. The within-person components are similar, although usually somewhat smaller. However, the restriction of the diastolic blood pressure range to 80-89 mmHg drastically alters the estimated between-person variability at baseline. The correlation between baseline measures of systolic blood pressure in this group is 0.55 (compared with 0.72 in the whole screening population), and that for diastolic blood pressure is only 0.004. The between-person covariances are also greatly reduced.
Variance components estimated from the data at 18 months, available only for blood pressure, are also presented in table 3. The within-person components are comparable with the estimates in both populations at baseline, while the between-person components lie between the previous two estimates, perhaps reflecting a continued but less extreme influence of the screening criteria at 18 months.
Estimates of the population cross-sectional reliabilities and covariance reliabilities in the screening data are given in table 4. The estimated reliability for a single measure at baseline is the same as the correlation between measures at different visits at baseline. In TOHP I, baseline measures of blood pressure were averaged over the three screening visits, and the excretions were averaged over two visits. If there were no selection at baseline, this would increase the reliabilities to 0.9 for the blood pressures, and to 0.5-0.6 for the excretion measures. The covariance reliabilities, a function of the between-and within-person covariances, are also given for each pair of measures. Most of these are greater than 0.7, except for those with \/K, which exhibits relatively greater withinperson covariances. Table 4 also shows the reliabilities of the change from baseline to 18 months in the TOHP I intervention data. These reliabilities are estimated for the change from the average of all available measures at baseline 0.63 * SBP, systolic blood pressure; DBP, diastolic blood pressure; Na, sodium; K, potassium; Na/K ratio, sodium/potassium ratio; VNl, square root transform of sodium; VR, square root transform of potassium; VNa/K ratio, square root transform of Na/K ratio; BMI, body mass index.
t Average of three measurements at a single visit.
to the average at 18 months, and are based on both the active sodium intervention and its control group. The reliabilities for change are uniformly lower than the estimated cross-sectional reliabilities of a single measure at baseline, and much lower than the reliabilities of the averages at baseline. The variance of the change depends on the extent of dietary behavior change in the population, reflected in the true change over time, as well as the random within-person variability. When the reliability was estimated separately for change in VNa in the active and control groups, these were 0.34 and 0.15, for the two groups, respectively. The overall reliabilities for change in sodium and change in Na/K ratio were lower than those of the * Cross-sectional reliability of a measure at a single visit. t SBP, systolic blood pressure; DBP, diastolic blood pressure; VNa, square root transform of sodium; VR, square root transform of potassium; VNa/K ratio, square root transform of Na/K ratio; BMI, body mass index.
$ Reliability of the change from average of measures at baseline to 18 months in the TOHP I sodium intervention and control groups combined.
§ Average of three measures at a single visit.
square root transforms, at 0.19 for each of the untransformed measures.
Corrected regression estimates
Observed coefficients in the regression of change in blood pressure from baseline to 18 months on change in excretions over the same period are given in table 5. There was little difference in the results from models with and without baseline excretion, so only those including these baseline values are given. Because of the severe lack of reliability of baseline measures of blood pressure in this randomized group, however, neither the observed nor adjusted models contain baseline blood pressure. Inclusion of baseline blood pressure, however, did not alter the observed regression coefficients. In the observed models, there was a significant association between each of the excretion measures and change in both systolic and diastolic blood pressure, except for VK with VNa in the model, which had a marginal association. The relation with VNa/K ratio was slightly stronger than with VNa for both systolic and diastolic blood pressure.
The coefficients corrected for measurement error are also given in table 5. These corrected coefficients for VNa and VNa/K ratio are all approximately three times the observed coefficients. Simpler univariate corrections to the observed coefficients, based on the reliabilities of change shown in table 4, led to similar, though larger, corrections. The estimated standard errors are roughly four times the observed estimates, due to uncertainty in the variance component estimation. The relations are thus generally less significant in the corrected data.
The corrected coefficient for VNa indicates a decrease in systolic/diastolic blood pressure of 0.85/0.54 mmHg per unit decrease in VNa (p = 0.047 for systolic blood pressure and p = 0.065 for diastolic blood pressure). When change in VK is added to this model, both the observed and corrected coefficients for VNa become more extreme, but less significant. This may be due to the limited reliability of both VNa and VK, as well as the correlation between them. The VNa/K ratio exhibits the most significant association with change in both systolic and diastolic blood pressure in these data, both for the observed and adjusted coefficients. When expressed as change per population standard deviation unit, the blood pressure effect is 3.7/1.9 mmHg for the VNa/K ratio compared with 2.4/1.6 mmHg for VNa. Regressions run only among participants in the active sodium reduction group yielded corrected coefficients that were consistent with these coefficients, though less significant.
When change in BMI was added to these models (table 6), change in VNa was no longer significant in either the observed or corrected models, but the adjusted coefficients were consistent with a possible effect. Change in the VNa/K ratio remained significant for systolic blood pressure {p = 0.03), with a somewhat diminished coefficient.
Comparison with other studies
To compare results of this analysis with those obtained from other studies, the estimates from the corrected models were translated back to the original scale for the excretion measures. The average sodium excretion level at baseline among participants in TOHP I was approximately 150 mmol/24 hours. A 100 mmol change in sodium excretion level would correspond to a change of 5.18 in VNa. The corrected estimated decreases in blood pressure per 100 mmol decrease in sodium excretion are then 4.4 mmHg for systolic and 2.8 mmHg for diastolic blood pressure (table 7). The corresponding decreases per 100 mmol decrease in sodium, adjusting for change in VK, are 9.8/4.6 mmHg, and 3.5/2.3 mmHg adjusting for change in BMI. Figure 2 shows the relation of change in sodium to change in systolic blood pressure in the observed and corrected models, and in the corrected model adjusted for change in BMI. These estimates are comparable with the corrected estimates from the Intersalt Study (11, 12) shown in table 7. The corrected TOHP I estimates are all slightly higher than the equivalent Intersalt estimates, especially for diastolic blood pressure.
Mean Na/K in the TOHP I population was approximately 2.7 units at baseline. A decrease of one unit corresponds to a decrease of 0.339 in VNa/K ratio. The corrected estimated decreases in blood pressure given this change are 3.4/1.7 mmHg (table 7) . These decrease to 2.8/1.3 mmHg after adjustment for change in BMI. The equivalent estimates from the Intersalt Study are 2.4/0.9 mmHg, lower than the TOHP I estimates, even without adjustment for BMI (11) .
We also estimated the overall intervention effect on blood pressure that would be expected given the change in VNa observed in TOHP I. The net change in sodium (the difference between the active intervention and its control group) at 18 months of follow-up was a decrease of 43.9 mmol/24 hours (15), with a corresponding decrease in VNa of 2.05 (mmol/24 hours) 1 ' 2 . The estimated effects of the intervention, based on the corrected model, would then be a decrease of 1.7/1.1 mmHg in systolic/diastolic blood pressure. The observed blood pressure effect in TOHP I at 18 months was a net decrease of 2.1/1.2 mmHg (15), indicating a reasonably good approximation to the observed group study data.
DISCUSSION
Measurement error corrections applied to crosssectional estimates of the relation of blood pressure and urinary sodium excretion have been subject to debate (12) (13) (14) . Criticisms of such correction in the Intersalt Study have included possible confounding by other uncontrolled cross-sectional covariates and a lack of correction for within-person covariability (13) . TOHP I offered an opportunity to address both of these concerns. The longitudinal design allowed us to examine the relation of changes in blood pressure to changes in excretion measures, which is less subject to confounding than cross-sectional observations. In addition, replicate measures of both blood pressure and excretions at baseline allowed us to estimate and correct for both the within-person variability and covariability of these measures. The estimated reliability, or contribution of between-person variance, was close to 40 percent for all excretion measures in the TOHP I screening data, comparable with those estimated from the Intersalt Study (27) and other studies (2) . The estimated covariance reliability (that is, the proportion of the total covariance of two measures at the same visit that is due to between-person covariance) was generally much higher. The within-person covariance between VNa and diastolic blood pressure was negligible, while that between VNa and systolic blood pressure was of marginal significance. Thus, correcting for this covariance would have little effect on regression estimates for sodium, particularly for diastolic blood pressure. The within-person covariances of VNa/K ratio and VK with blood pressure, however, were higher, suggesting that correction for these would have a greater impact. Correcting only for within-person variance for VNa/K ratio leads to an estimated effect on systolic/diastolic blood pressure of 4.0/2.1 mmHg per unit change in Na/K compared with 3.4/1.7 mmHg when correction for the covariance is also made.
Correction for within-person variability may be even more important in longitudinal data based on measures of change than with cross-sectional measures. The reliabilities of change in Na or blood pres-sure from baseline to 18 months in the TOHP I data are uniformly lower than the corresponding crosssectional reliabilities. The degree of true change over time, as opposed to short-term within-person variability, depends on the intervention applied. For participants in the active sodium intervention in TOHP I, the reliability of change was 34 percent for VNa, while the corresponding reliability in the control group was only 15 percent. Most of the apparent change in the control group can be attributed to short-term withinperson variability. The fact that this estimate was non-zero suggests that using the variance over time in the control group as a measure of short-term measurement variability may be an overestimate because it includes some longer-term variation. While the reliability for BMI at baseline was very high, 0.98, that for change was reduced to 0.77. An intervention explicitly designed to lower BMI would likely lead to a higher reliability of change in this variable.
Estimated dose-response relations were obtained after adjustment for the within-person variances and covariances. While the square-root transform introduced a slight convex curve to the relation of sodium to blood pressure, the relation was not far from linear, and the fit of the linear model was very similar (see figure 2) . A linear relation was also reported in the Intersalt Study (3) and in data from the active intervention group in TOHP I (15) .
The adjusted estimates suggested a decrease of 4.4/ 2.8 mmHg in systolic/diastolic blood pressure with a 100 mmol/24 hour decrease in sodium. These data agree with the group data from TOHP I. The estimates were similar for systolic blood pressure, and slightly larger for diastolic blood pressure when compared with corrected estimates from the cross-sectional data in the Intersalt Study. In a meta-analysis of doseresponse using group data across studies, Cutler et al. (8) estimated decreases among normotensives of 2.3 mmHg for systolic blood pressure and 1.4 mmHg for diastolic blood pressure per 100 mmol decrease in sodium excretion. Cutler et al.'s estimates (8) were lower than those reported here, and may have been attenuated by missing data for non-compliers to the interventions. This problem may have affected the intervention group means from TOHP I as well.
In these data, it appears that change in potassium also affects the sodium-blood pressure relation. Analyses using VNa/K ratio demonstrated stronger doseresponse, and remained significant for systolic blood pressure even after adjustment for BMI. This is also consistent with data from the Intersalt Study, in which the estimated effect of sodium excretion increased after adjustment for potassium excretion (12) . In addition, the relation of blood pressure with Na/K was statistically as strong or stronger than that with sodium itself (11) .
The estimated changes in blood pressure per 100 mmol/24 hour reduction in sodium could have significant impacts on cardiovascular heart disease incidence if achieved in a population and maintained over time (28, 29) . However, recent evidence from Phase II of TOHP (30) suggests that such changes may be difficult to realize in the context of our current food supply. The net decrease in sodium excretion at 6 months from a baseline average of 184 mmol/d was only 50 mmol/d in the sodium intervention group and 37 mmol/d in a combined intervention group, and the recidivism over a 36-month period was about 20 percent in the sodium intervention and 35 percent in the combined intervention, respectively. This difficulty in achieving and maintaining sodium reduction is likely related to the widespread presence of sodium in processed foods, the source of 75-80 percent of dietary sodium. The present data indicate, however, consistent evidence for an important biologic effect of sodium reduction on blood pressure at least over an 18-month period. 
Variance structure
These baseline parameters may be fit using a multivariate model. For a single blood pressure measure (e.g., systolic blood pressure) and a single excretion measure (e.g., VNa), data for each person includes the 5X1 vector of three observed blood pressures and two excretions measured at the screening visits. The mean vector is a function of fx m and JLL XO , including their explanatory covariates. The variance matrix is a 5 X 5 matrix whose upper diagonal form is as follows: A similar structure was fit to the 10X1 vector containing measures of systolic and diastolic blood pressure, VNa, and VK at baseline. In this larger model, both between-and within-person components were also fit to the covariance between systolic and diastolic blood pressure and between VNa and VK. A separate but similar model was fit to the 18-month blood pressure data to estimate the between-and within-person variances of blood pressure at that time. All models were fit with program 5V of BMDP using Fortran subroutines to fit the variance structure (23) . Maximum likelihood estimates were obtained using the Newton-Raphson algorithm. Restricted maximum likelihood estimation produced nearly identical results, but took longer to achieve convergence in this large data set.
APPENDIX 2
Within-person variances of means and changes
In TOHP I, blood pressure was averaged over three screening visits at both baseline (SV1-SV3) and 18 months. Excretion data were averaged over two baseline visits (SV3 and SRV), with a single measure available at 18 months. The within-person variances and covariances of the means are divided by the appropriate number of visits at each time. For measures of change, the within-person variances and covariances are a function of the components at both baseline and 18 months. These were allowed to be different for blood pressure due to the screening selection at baseline, and were estimated from the baseline and 18-month data of the randomized participants. For the 18-month excretions, because only a single urine collection was available at this time, the within-person variance of the excretion measures and their covariance with blood pressure at this time were estimated from the total screened population at baseline. wu represents the within-person covariance of VK with blood pressure and o^v represents the within-person covariance of VNa and VK. In each regression, the S uu matrix used is the submatrix composed of all within-person variances and covariances for the predictor variables used in each particular model, and S uw is the vector of within-person covariances of these terms with change in blood pressure. All models were run separately for systolic and diastolic blood pressure.
APPENDIX 3
Variance of adjusted estimate
The variance of the adjusted regression estimator /3 adj is adapted from Fuller (25) . Let Y t be the average blood pressure change from baseline to 18 months for person i, and X, be ap X 1 vector of explanatory variables, some of which are measured with error. The coefficient vector /3 adj is also of dimension p X 1. The terms in equation 3 may then be written as The term n stands for the number of individuals i, and df stands for the degrees of freedom available for estimating the within-person variance components. In these data, these components were estimated from different sources, each of which included at least n individuals. As a conservative estimate, therefore, we have substituted n for df in this equation.
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